skip to main content

Denosumab-associated hypocalcaemia in severe chronic kidney disease — SCE Geriatric Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal MedicineDenosumab-associated hypocalcaemia in severe chronic kidney diseaseSCE Geriatric Medicine

An 84-year-old woman attends for her scheduled sixth-monthly denosumab injection. She has severe osteoporosis with two previous vertebral fractures and has received denosumab for 5 years. She has stage 4 chronic kidney disease (eGFR 18 mL/min/1.73 m²). Following a recent diarrhoeal illness, she stopped taking calcium and colecalciferol. She now reports perioral tingling and intermittent hand spasms. Corrected calcium is 1.84 mmol/L, phosphate 1.6 mmol/L and magnesium 0.82 mmol/L. Her previous denosumab injection was exactly 6 months ago. What is the most appropriate management of her osteoporosis treatment today?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Withhold denosumab, urgently correct the hypocalcaemia and obtain specialist review for prompt ongoing antiresorptive treatment once calcium is stable

Denosumab must not be administered in the presence of hypocalcaemia. This patient has symptomatic, marked hypocalcaemia, and her severe renal impairment further increases the risk of severe or fatal denosumab-associated hypocalcaemia. The immediate priority is therefore to withhold the injection and correct the biochemical disturbance urgently. However, simply stopping or substantially delaying denosumab is also hazardous. She has received long-term therapy and has previous vertebral fractures, placing her at particularly high risk of multiple vertebral fractures following interruption. Specialist review should therefore secure the shortest safe interruption and determine whether denosumab can be resumed after calcium and vitamin D repletion or whether another specialist-selected strategy is required. A ignores an explicit contraindication: supplementation given alongside denosumab does not make administration safe while she is already hypocalcaemic. C and E expose her to rebound bone turnover and vertebral fractures without protective treatment. D recognises the need for antiresorptive cover but zoledronic acid is contraindicated when creatinine clearance is below 35 mL/min and is also contraindicated in hypocalcaemia. The distinction-level decision is to prioritise correction of the immediate metabolic danger while avoiding an unplanned, prolonged denosumab interruption.

Reference: Prolia 60 mg solution for injection — Summary of Product Characteristics (17 July 2026) — https://www.medicines.org.uk/emc/product/568/smpc Denosumab 60 mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment (August 2020) — https://assets.publishing.service.gov.uk/media/5f465ff3d3bf7f3d651d8b89/Aug-2020-DSU-PDF.pdf Aclasta 5 mg solution for infusion — Summary of Product Characteristics (19 June 2026) — https://www.medicines.org.uk/emc/product/210/smpc